Tag

Seladelpar

All articles tagged with #seladelpar

business-pharmaceuticals2 years ago•1 min saved

Gilead's $4.3 Billion Acquisition of CymaBay Signals Major Move in Liver Disease Treatment

Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment, seladelpar, with potential blockbuster sales. The deal comes as Gilead seeks growth beyond its core HIV business and follows setbacks in clinical trials for other drugs. The acquisition is expected to complement Gilead's portfolio of liver disease treatments and is anticipated to be neutral to Gilead's earnings in 2025.

via CNBC|

#acquisition #business-pharmaceuticals #cymabay-therapeutics

health-and-pharmaceuticals2 years ago•10 min saved

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

Gilead Sciences has announced the acquisition of CymaBay Therapeutics for $4.3 billion, adding seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to its liver portfolio. Seladelpar, with FDA priority review and anticipated U.S. approval in the third quarter of 2024, has shown promising results in Phase 3 trials, offering a potential treatment for PBC, a rare liver disease. The acquisition aligns with Gilead's commitment to addressing unmet needs in liver diseases and is expected to enhance its revenue growth upon FDA approval of seladelpar.

via Gilead Sciences|

#acquisition #cymabay-therapeutics #gilead-sciences